CEDUR — German inflammatory bowel disease registry
Long-term Observation of IBD Patients, a Nationwide German IBD Registry "CEDUR"
This registry collects real-world health and treatment information from adults with Crohn's disease, ulcerative colitis, or indeterminate colitis in Germany to see how care, effectiveness, safety, and costs play out in routine practice.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | ImmunoRegister gUG Academic / other |
| Locations | 1 site (Hamburg) |
| Trial ID | NCT07319442 on ClinicalTrials.gov |
What this trial studies
CEDUR is a multicenter, web-based, prospective registry enrolling adult patients with Crohn's disease, ulcerative colitis, or indeterminate colitis across Germany. Physicians and patients provide clinical data, quality-of-life measures, treatment patterns, and safety outcomes during routine care. The registry also captures pharmacoeconomic information to study cost and resource use over time. Aggregated data are used to monitor care quality and long-term therapy outcomes under real-world conditions.
Who should consider this trial
Good fit: Adults in Germany diagnosed with Crohn's disease, ulcerative colitis, or indeterminate colitis who receive care from participating physicians are the intended participants.
Not a fit: Patients with other gastrointestinal disorders, pediatric patients, or people not receiving care at participating centers (including those outside Germany) are unlikely to benefit from participation or enrollment.
Why it matters
Potential benefit: If successful, the registry could help doctors and patients choose and manage long-term treatments by revealing real-world effectiveness, safety, and cost patterns.
How similar studies have performed: Other national and international IBD registries have provided valuable real-world insights into treatment effectiveness, safety, and healthcare use, so this approach is established rather than novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Crohn Disease Ulcerative Colitis Indterminate Colitis Exclusion Criteria: * Other gastrointestinal disorders than above
Where this trial is running
Hamburg
- ImmunoRegister gUG — Hamburg, Germany (Recruiting)
Study contacts
- Principal investigator: Stefanie Howaldt, MD — ImmunoRegister gUG
- Study coordinator: Stefanie Howaldt, MD
- Email: Howaldt@immunoregister.de
- Phone: +4940423265150
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.